StockData

Karman vs Rocket Lab

KRMN and RKLB side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRMN and RKLB compare

Rocket Lab is the larger company, worth 7.0 times as much as Karman ($32.9B against $4.7B).

Karman grew revenue faster over the last twelve months (56.3% versus 52.5% for Rocket Lab).

Karman keeps more of each dollar of sales as profit, with a net margin of 7.5% compared with −21.5% at Rocket Lab.

Karman scores higher on the StockData Score (10 against 8 for Rocket Lab), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRMNRKLB
Size and price
Market cap$4.7B$32.9B
Share price$35.55$55.05
Change, 1 year−41.0%20.9%
Change, 5 years–256%
Beta (5Y)1.564.35
Employees1,4002,600
StockData Score
Total score10 (better)8
Valuation score00
Growth score4 (better)3
Performance score4 (better)2
Health score23 (better)
Dividend score00
Valuation
P/E91.2×–
P/S7.0× (better)42.8×
P/B10.7×9.4× (better)
EV/EBITDA32.4×–
FCF yield−0.16% (better)−1.1%
Fair value$11.29$19.24
Margin of safety−215%−186% (better)
Growth
Revenue growth (TTM)56.3% (better)52.5%
Revenue growth, 5Y average–76.5%
Net income growth (TTM)345%–
EPS growth (TTM)388%–
Profitability
Gross margin42.1% (better)37.3%
Operating margin16.3% (better)−29.1%
Net margin7.5% (better)−21.5%
FCF margin−1.1% (better)−48.3%
Return on equity12.4% (better)−7.9%
Return on invested capital10.3% (better)−28.1%
Financial health
Debt / equity1.940.00 (better)
Net debt / EBITDA4.65–
Interest coverage1.9×–
Current ratio3.105.48 (better)
Altman Z-score3.2528.74 (better)
Piotroski F-score66
Dividends and buybacks
Buyback yield–−6.9%
Shareholder yield0.00% (better)−6.9%
Ownership
Held by institutions93.8%53.9%
Held by insiders62.2%16.3%
Insider net buying, 12 months−$9.2M (better)−$682M
Short interest, % of float38.6%9.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.